MetaADEDB 2.0 @ LMMD
azosemide
(HMEDEBAJARCKCT-UHFFFAOYSA-N)
Structure
SMILES
Clc1cc(NCc2cccs2)c(cc1S(=O)(=O)N)c1n[nH]nn1
Type(s)
Investigational
Molecular Formula:
C12H11ClN6O2S2
Molecular Weight:
370.838
Log P:
3.6952
Hydrogen Bond Acceptor:
8
Hydrogen Bond Donor:
3
TPSA:
163.27
CAS Number(s):
27589-33-9
Synonym(s)
1.
azosemide
2.
5-(4-chloro-5-sulfamyl-2-thienylaminophenyl)tetrazole
3.
BM 02.001
4.
Ple 1053
5.
azosemid
External Link(s)
MeSHC018222
PubChem Compound2273
ChEBI31248
CHEMBLCHEMBL1097235
DrugBankDB08961
DrugCentral278
KEGGdr:D01323
Therapeutic Target DatabaseD04LYD
ZINC5843546
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Acute bronchitisOFFSIDES
2Acute prerenal failureOFFSIDES
3Alcoholic IntoxicationOFFSIDES
4Altered state of consciousnessOFFSIDES
5AmphetaminesOFFSIDES
6AngioplastyOFFSIDES
7ApneaOFFSIDES
8AscitesOFFSIDES
9AsphyxiaOFFSIDES
10Aspiration PneumoniaOFFSIDES
11Atrial FlutterOFFSIDES
12Blood aldosterone increasedOFFSIDES
13Blood alkaline phosphatase decreasedOFFSIDES
14Blood creatinine increasedOFFSIDES
15Blood glucose decreasedOFFSIDES
16Blood parathyroid hormone increasedOFFSIDES
17Blood sodiumOFFSIDES
18Blood urea increasedOFFSIDES
19Blood uric acidOFFSIDES
20BradycardiaOFFSIDES
21Breast cancer recurrentOFFSIDES
22Cold sweatOFFSIDES
23Creatinine renal clearance decreasedOFFSIDES
24Cytomegalovirus enterocolitisOFFSIDES
25DehydrationOFFSIDES
26Depressed Level of ConsciousnessOFFSIDES
27Disease ProgressionOFFSIDES
28Disseminated Intravascular CoagulationOFFSIDES
29DrowningOFFSIDES
30Duodenal UlcerOFFSIDES
31Enterocolitis viralOFFSIDES
32Femoral artery occlusionOFFSIDES
33GangreneOFFSIDES
34GastroenteritisOFFSIDES
35Gaze palsyOFFSIDES
36Hearing Loss4088324CTD
37Hepatitis BOFFSIDES
38HepatitisOFFSIDES
39Histiocytosis haematophagicOFFSIDES
40Hypereosinophilic syndromeOFFSIDES
41InfectionOFFSIDES
42Lymphangiosis carcinomatosaOFFSIDES
43MyelodysplasiaOFFSIDES
44Nephrotic SyndromeOFFSIDES
45Neuroleptic Malignant SyndromeOFFSIDES
46OliguriaOFFSIDES
47Oxygen saturation abnormalOFFSIDES
48PO2 decreasedOFFSIDES
49Pneumocystis jiroveci pneumoniaOFFSIDES
50PoriomaniaOFFSIDES
51Protein total decreasedOFFSIDES
52Psychiatric symptomOFFSIDES
53Respiratory FailureOFFSIDES
54RhabdomyolysisOFFSIDES
55Shunt malfunctionOFFSIDES
56Shunt occlusionOFFSIDES
57Sick Sinus SyndromeOFFSIDES
58Subcutaneous AbscessOFFSIDES
59Sudden deathOFFSIDES
60Therapy non-responderOFFSIDES
61Troponin TOFFSIDES
62Vertebrobasilar InsufficiencyOFFSIDES
63YawningOFFSIDES
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.